Advancing a class on top of statins
Investors & Media

Investor Overview

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

NASDAQ | GEMP (Common Stock)

$5.86

 0.07 (1.18%)

High$5.94
Low$5.79
Volume24,750
Market Cap$83,363,774

04/20/18  3:59 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: GEMP.O.  Currently trading at $5.86 with a 52 week high of $21.59 and a 52 week low of $5.55.

Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(C)(4)

04/12/18

Read More

Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results

03/15/18

Read More

Gemphire Therapeutics to Announce Fourth Quarter and Year End 2017 Financial Results on Thursday, March 15

03/13/18

Read More


There are currently no events scheduled.